Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Revenue (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Revenue for 4 consecutive years, with $196.0 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 39099.8% to $196.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $638.5 million through Dec 2025, up 138.76% year-over-year, with the annual reading at $638.5 million for FY2025, 65.55% up from the prior year.
  • Revenue hit $196.0 million in Q4 2025 for Axsome Therapeutics, up from $171.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $196.0 million in Q4 2025 to a low of $500000.0 in Q4 2024.
  • Historically, Revenue has averaged $81.8 million across 4 years, with a median of $75.0 million in 2024.
  • Biggest five-year swings in Revenue: crashed 99.3% in 2024 and later skyrocketed 39099.8% in 2025.
  • Year by year, Revenue stood at $24.4 million in 2022, then surged by 193.5% to $71.5 million in 2023, then plummeted by 99.3% to $500000.0 in 2024, then surged by 39099.8% to $196.0 million in 2025.
  • Business Quant data shows Revenue for AXSM at $196.0 million in Q4 2025, $171.0 million in Q3 2025, and $150.0 million in Q2 2025.